Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 mai 2024 16h00 HE
|
Mural Oncology, Inc.
WALTHAM, Mass and DUBLIN, May 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and...
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24 avr. 2024 16h00 HE
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, Ireland, April 24, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered...
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
09 avr. 2024 16h00 HE
|
Mural Oncology, Inc.
Mural Oncology, a clinical-stage immuno-oncology company, shared pre-clinical data from its Interleukin-18 (IL-18) and IL-12 programs at AACR today.
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 avr. 2024 16h00 HE
|
Mural Oncology, Inc.
WALTHAM, Mass. and DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell...
Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
26 mars 2024 07h00 HE
|
Mural Oncology, Inc.
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company announces Q4 and YE 2023 financial results and provides business update.
Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
05 mars 2024 16h35 HE
|
Mural Oncology, Inc.
DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 mars 2024 16h15 HE
|
Mural Oncology, Inc.
DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein...
Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference
27 févr. 2024 07h00 HE
|
Mural Oncology, Inc.
DUBLIN, Ireland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 févr. 2024 16h30 HE
|
Mural Oncology, Inc.
DUBLIN, Ireland, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein...
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
08 janv. 2024 07h00 HE
|
Mural Oncology, Inc.
Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful dataMural intends to nominate development...